CRF Health’s TrialMax eCOA Solution Selected for Landmark Pain Outcomes Study


Applied Clinical Trials

CRF Health announced that its TrialMax Touch and TrialMax Slate solutions have been selected by a Global Category Japanese Pharmaceutical company for a pain outcomes study. The Phase III trial will involve 800 screened and 320 randomized subjects across 40 sites in the US.

Read the full release here.

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Related Content
© 2024 MJH Life Sciences

All rights reserved.